A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Atezolizumab (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- 22 Nov 2023 Planned End Date changed from 21 Nov 2023 to 21 Nov 2024.
- 22 Nov 2023 Planned primary completion date changed from 21 Nov 2023 to 21 Nov 2024.
- 01 Apr 2023 Status changed from recruiting to active, no longer recruiting.